AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01292187
Drug: Oral placebo at bedtime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo at bedtime
Trial: NCT03031444
Drug: FOLFIRI/FOLFOX/CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
Trial: NCT00243750
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00667745
Drug: Optimized Treatment (OPT)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
Trial: NCT01884636
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT04013646
Drug: Umbilical cord blood infusion
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Trial: NCT04013646
Drug: Placebo umbilical cord blood infusion
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Trial: NCT01063517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg BID oral tablet to match olaparib tablet
Trial: NCT01682200
Drug: ProOxy
RxNorm normalized name: 2-propoxy-1-propanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
Trial: NCT03547804
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
Trial: NCT00255437
Drug: ferumoxytol or oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03119636
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa is used depending on the patient's condition
Trial: NCT01366898
Drug: Dexamethasona, Idarubicine, ARA-C, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01725490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
Trial: NCT02550067
Drug: LNG
RxNorm normalized name: Jobst Knee High White LNGT Beige Small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
Trial: NCT03742973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00166829
Drug: sirolimus, tacrolimus, mycophenolate mofetil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03221569
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
Trial: NCT01861626
Drug: V0057 - A mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT01155336
Drug: Lovaza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza® is prescription grade EPA+DHA fish oil supplement.
Trial: NCT00207311
Drug: Xenical, Pegasys, Copegus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
Trial: NCT03221569
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine.
Trial: NCT02360826
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02360826
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03221569
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml intravenous push as placebo for double-blinding purposes
Trial: NCT03619616
Drug: ZSP1603 7.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1603 capsule administered orally once daily under fasted condition.
Trial: NCT01695135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 tablets) taken orally once daily
Trial: NCT03619616
Drug: ZSP1603 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1603 capsule administered orally once daily in the fasting state.
Trial: NCT01488526
Drug: TDF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
Trial: NCT01434173
Drug: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
Trial: NCT02031510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transversus abdominis plane block with saline 0.9%
Trial: NCT00490269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03619616
Drug: ZSP1603 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1603 capsule administered orally once daily under fasted condition.
Trial: NCT03619616
Drug: Placebo 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
Trial: NCT00269516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01101152
Drug: Desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day
Trial: NCT00726999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02675920
Drug: non-ionic monomer iodinated CT contrast media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
Trial: NCT01820195
Drug: Oral N-Acetyl Cystein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
Trial: NCT01820195
Drug: IV N-Acetyl Cystein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
Trial: NCT01820195
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this group will be received both oral placebo and IV placebo
Trial: NCT03591926
Drug: SM04646
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week.
Trial: NCT00837200
Drug: Oncaspar, Doxil, Decadron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
Trial: NCT02182934
Drug: Ginsana
RxNorm normalized name: Ginsana 200mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04247230
Drug: STUD100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Trial: NCT00666055
Drug: ARV regimen chosen by treating physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).
Trial: NCT04146038
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01418118
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
Trial: NCT01418118
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
Trial: NCT01470456
Drug: SAR3419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for infusion Route of administration: Intravenous
Trial: NCT02782286
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients randomised to this arm will receive 30 mg intravenous ketorolac.
Trial: NCT02727907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
Trial: NCT02515851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01098032
Drug: Systemic alone therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
Trial: NCT01587144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
Trial: NCT03794180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
Trial: NCT00382135
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth once a day for 40 weeks
Trial: NCT03034915
Drug: UMEC/VI 62.5/25 mcg via ELLIPTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
Trial: NCT03034915
Drug: UMEC 62.5 mcg via ELLIPTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
Trial: NCT03034915
Drug: Placebo via ELLIPTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
Trial: NCT03034915
Drug: Placebo via DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Trial: NCT00714558
Drug: Fentanyl citrate; Naltrexone; Naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00534560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets; 4 week dose titration with 16 weeks at target dose
Trial: NCT00424762
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blinded treatment with matching placebo
Trial: NCT00246012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
Trial: NCT00853827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01673425
Drug: Live Attenuated Influenza Vaccine
RxNorm normalized name: Live attenuated influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be given FluMist.
Trial: NCT03216395
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
Trial: NCT03228992
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
Trial: NCT00978237
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills QD VO
Trial: NCT00250341
Drug: Servent Diskus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg
Trial: NCT00241722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03965013
Drug: NNC0268-0965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
Trial: NCT03965013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo given in Part 1
Trial: NCT03117855
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02690350
Drug: U3-1784
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Trial: NCT04339816
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally or into nasogastric tube for 5 days
Trial: NCT04339816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally or into nasogastric tube for 5 days
Trial: NCT02618317
Drug: Minocycline-EDTA 30 mg/ml - 3 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
Trial: NCT02273661
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An aerosol of isotonic saline x 1/ week will be administered during 6 months
Trial: NCT01716949
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
Trial: NCT04981379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Trial: NCT00786318
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haldol 5mg/ Ativan 2mg IM
Trial: NCT01787240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00116623
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01640782
Drug: Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.
Trial: NCT01640782
Drug: Leucovorin, 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.
Trial: NCT01023373
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypotensive drugs, statins and anti-platelets
Trial: NCT02386982
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04485156
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/kg
Trial: NCT00427167
Drug: AMA1-C1/Alhydrogel + CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00137293
Drug: GAP-486 (ZP-123)
RxNorm normalized name: GAP JUNCTION ALPHA-3 PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00295542
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril)
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at awakening versus bedtime
Trial: NCT01194154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
Trial: NCT00295542
Drug: ARB (including valsartan, telmisartan, olmesartan)
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at awakening versus bedtime
Trial: NCT03219645
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Trial: NCT00878722
Drug: PXD101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03369704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
Trial: NCT00795704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg #2 capsules by mouth three times daily